Transthyretin amyloid cardiomyopathy

There are 44 papers on transthyretin amyloid cardiomyopathy in aging research: 5 trials and 25 observational studies in people, 12 reviews. The newest story, Nov 12, 2026: “Drug class tied to lower death risk on tafamidis in heart amyloidosis”.

Disease

44 papers study it3 more mention it9 findings

13 new papers in 30 daysSee all 47 papers on transthyretin amyloid cardiomyopathy

“It had good discrimination for ATTR-CM detection with an area under the receiver operator characteristic curve of 0.85 (5-fold cross-validation, 0.77-0.85) in the internal set”
Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical TrialJAMA cardiology2025doi:10.1001/jamacardio.2025.4591
  • Human trial5
  • Humans25

Associations

8

Ai-ecg

upin humans1upin silico1

2 studies
  1. Ai-ecg predicts transthyretin amyloid cardiomyopathy in humans (ATTR-CM ascertainment at most 1 year after the index ECG) (AUROC 0.78 (95% CI 0.75-0.80)).

    HumansATTR-CM ascertainment at most 1 year after the index ECGn = 1,458

    Software flags possible unrecognized heart disease in US adults

    AHA Scientific Sessions 2026 abstract
  2. Ai-ecg predicts transthyretin amyloid cardiomyopathy in silico (internal test set) (AUROC 0.87 (95% CI 0.82–0.91)).

    In silicointernal test setn = 20,222

    AI detects cardiac amyloidosis from heart tracing images

    ESC Congress 2026 abstract

More on Ai-ecg

Ai-echo

upin humans1

1 study
  1. Ai-echo predicts transthyretin amyloid cardiomyopathy in humans (Participants with valid ATTR information) (AUROC 0.88).

    HumansParticipants with valid ATTR informationn = 525

    Software flags possible unrecognized heart disease in US adults

    AHA Scientific Sessions 2026 abstract

More on Ai-echo

Deep learning AI-ECG model

upin humans1

1 study
  1. deep learning AI-ECG model predicts transthyretin amyloid cardiomyopathy in humans (internal temporal validation) (AUROC 0.84 (95% CI, 0.79-0.89)).

    Humansinternal temporal validationn = 44,123

Alzheimer's disease

downin humans1OR 0.65

1 study
  1. Transthyretin amyloid cardiomyopathy is associated with Alzheimer's disease in humans (adjusted for major dementia risk factors) (OR 0.65, 99% CI 0.56-0.75).

    Humansadjusted for major dementia risk factorsn = 96,200

More on Alzheimer's disease

Amyloid deposition

upin humans1

1 study
  1. Amyloid deposition is associated with transthyretin amyloid cardiomyopathy in humans (carpal tunnel amyloid-positive) (28% (32/116)).

    Humanscarpal tunnel amyloid-positivemyocardiumn = 116

More on Amyloid deposition

Hospitalization

upin humans1+46%

1 study
  1. Transthyretin amyloid cardiomyopathy is associated with hospitalization in humans (ATTR-CM) (46%).

    HumansATTR-CM1-year follow-upn = 867

Mortality

upin humans1+13%

1 study
  1. Transthyretin amyloid cardiomyopathy is associated with mortality in humans (ATTR-CM) (13%).

    HumansATTR-CM1-year follow-upn = 867

Attractnet

upin humans1

1 study
  1. Attractnet predicts transthyretin amyloid cardiomyopathy in humans (internal test set) (AUC 0.85).

    Human trialinternal test set

More on Attractnet

Trial sponsors

Funding

1 grant since 2026

National Heart, Lung, and Blood Institute$171K

Latest

Dec 2025: 2Jan 2026: 6Feb 2026: 1Mar 2026: 1Apr 2026: 0May 2026: 2Jun 2026: 1Jul 2026: 2Aug 2026: 2Sep 2026: 3Oct 2026: 9Nov 2026: 433 papers in 12 months
Archives of Cardiovascular Diseases

Drug class tied to lower death risk on tafamidis in heart amyloidosis

Sodium-glucose cotransporter 2 inhibitors were linked to lower relative death rates versus nonuse, with hazard ratios of 0.56 at one year and 0.62 at five years.Sodium-glucose cotransporter 2 inhibitors were linked to lower relative death rates versus nonuse, with hazard ratios of 0.56 at one year and 0.62 at five years.

Cohort · 5,683 peopleInterventions
AHA Scientific Sessions 2026 Abstract

Software flags possible unrecognized heart disease in US adults

Screening heart electrical recordings flagged 12,517 adults (4.8%) without confirmed disease as probable cases of a condition involving protein buildup in the heart.Screening heart electrical recordings flagged 12,517 adults (4.8%) without confirmed disease as probable cases of a condition involving protein buildup in the heart.

Cohort · 289,848 peopleBiomarkers
ESC Congress 2026 Abstract

AI detects cardiac amyloidosis from heart tracing images

The model achieved a score of 0.87 for distinguishing cases from noncases in an internal test set of 20,222.The model achieved a score of 0.87 for distinguishing cases from noncases in an internal test set of 20,222.

Cohort · 20,222 peopleCardiac amyloidosis
ESC Congress 2026 Abstract

AI screening flags probable undiagnosed heart disease

Electrocardiogram models flagged probable disease in 4.8% of 201,475 people, while heart ultrasound models flagged 6.4% of 6,692 people.Electrocardiogram models flagged probable disease in 4.8% of 201,475 people, while heart ultrasound models flagged 6.4% of 6,692 people.

Cohort · 203,655 peopleBiomarkers

See all 47 papers on transthyretin amyloid cardiomyopathy